

Cell & Gene Therapy

October 15, 2025
VIRTUAL EVENT SERIES



Date	Time	Track	Presentation Title	Speaker
15-Oct	05:30 - 06:30 AM		Non-viral, large-scale delivery of gene editing tools for T-cell manufacturing	Stefanie Muethel, PhD Team Lead R+D, Lonza Andrea Toell, PhD Associate Director Portfolio Management, Lonza
15-Oct	06:00 - 07:00 AM	Emerging Therapeutic Modalities: Current Practices, Challenges, Novel Solutions	Seed train and bioprocess strategies for suspension cell culture-based adeno-associated virus production	Ines Hartmann Application Specialist Cell Handling, Eppendorf SE Dr. Stefan Schlößer Scientific Communications Manager
15-Oct	06:30 - 07:30 AM	Emerging Therapeutic Modalities: Current Practices, Challenges, Novel Solutions	Monitoring and evaluating CAR-T cells in patient cohorts	Raquel Munoz Garcia, PhD Immunologist, Hospital Universitario Virgen del Rocío
15-Oct	07:30 - 08:30 AM	Emerging Therapeutic Modalities: Current Practices, Challenges, Novel Solutions	Keynote Presentation: CRISPR Meets iPSCs: Powering the New Wave of Biomedical Discovery	Dr. Pia Johansson Director of the Cell and Gene Technologies Core (CAGT core) at Lund Stem cell Centre at Lund University
15-Oct	09:00 - 10:00 AM	Emerging Therapeutic Modalities: Current Practices, Challenges, Novel Solutions	Keynote Presentation: Outsmarting the Escape Artist: Resistance in CAR T-Cell Therapy for Hematologic Cancers w/ Live Q&A	Marco Ruella, MD Associate Professor of Medicine; Scientific Director, Lymphoma Program; University of Pennsylvania
15-Oct	10:00 - 11:00 AM	Bioanalysis of Novel Therapeutic Modalities: Advancements and Challenges	De-Risking Gene Therapy Development: Stress Testing Viral Vectors with Mass Photometry Analysis	Hena Divanovic Applications Scientist, Refeyn
15-Oct	11:00 - 12:00 PM	Revolutionary Technologies: Present and Future of Cell and Gene Therapy	Cell Therapy Cryogenics: Moving Beyond the DMSO Era	Steve Oh, PhD Independent Cell Therapy Leader

15-Oct	12:00 - 01:00 PM		Networking Hour	Join Us for Networking Opportunities!
15-Oct	12:00 - 01:00 PM		Optimizing dsRNA Removal in IVT mRNA: Strategies for Enhanced Translation and Reduced Immunogenicity	Johnathan Parker, BS Senior R&D Scientist, CELLSCRIPT™
15-Oct	12:30 - 01:30 PM	Emerging Therapeutic Modalities: Current Practices, Challenges, Novel Solutions	Advance Your Cell Therapy With Innovative CRISPR & mRNA-LNP Tools	Daksha Patel, PhD Senior Segment Marketing Manager, Cell Therapy, GenScript USA Inc. Fengmei Pi, PhD Head of Product Development and Manufacturing, GenScript Innovation Center
15-Oct	01:00 - 02:00 PM	Development of Cell and Gene Therapies to Treat, Prevent, and Potentially Cure Diseases	Optimizing iPSC-derived cell therapy development for allogeneic and therapeutic applications	Dr. Omar Farah Manager, Field Applications at Thermo Fisher Scientific
15-Oct	01:15 - 02:15 PM	Bioanalysis of Novel Therapeutic Modalities: Advancements and Challenges	Analytical Assays with qPCR and dPCR in CGT Development, Characterization, and Regulatory Compliance	Lee Landeen, PhD Executive Director, Pre-clinical Development at Angiocrine Bioscience
15-Oct	02:00 - 03:00 PM		Advanced Gene Therapy Development Solutions: A Comprehensive Platform for Next-Generation Therapeutic Innovation / Novel Viral Vectors Solutions	Roumen Bogoev, MSc Head of Segment Marketing, GenScript USA Yang Xiang, PhD Field Application Scientist Lead
15-Oct	02:30 - 03:30 PM		Unlock Cell Therapy Potential with Customizable Cell Isolation and Enhanced T cell Activation Solution	Vevian Zhang, M.S. Sr. Product Manager, GenScript
15-Oct	03:00 - 04:00 PM		Robotic Automation of Cell Isolation to Streamline Cell Therapy Manufacturing	Dr. Fred Parietti Co-founder and CEO of Multiply Labs
15-Oct	03:15 - 04:15 PM	Development of Cell and Gene Therapies to Treat, Prevent, and Potentially Cure Diseases	Securing Cell Therapy Success: The Role of PCR in Quality Control	Dr. Shiqian Zhu Director of CMC Bioanalytical, BioAgilytix Dr. Amanda Hays Scientific Officer and Senior Director, BioAgilytix
15-Oct	On Demand	Emerging Therapeutic Modalities: Current Practices, Challenges, Novel Solutions	Efficient base editing in cystic fibrosis airway epithelial cells	Ashley Cooney, PhD Assistant Professor, The University of Iowa

15-Oct	On Demand	Emerging Therapeutic Modalities: Current Practices, Challenges, Novel Solutions	Mapping CAR T Cell Therapy: Strategies to Maximize Expansion, Persistence, Trafficking & Efficacy/Mapping CAR T: Maximizing Expansion, Persistence & Trafficking	Joseph A. Fraietta, PhD Assistant Professor of Microbiology; Adjunct Assistant Professor of Pathology; Director of Translational & Correlative Sciences, Center for Cellular Immunotherapies, Abramson Cancer Center, University of Pennsylvania
15-Oct	On Demand	Development of Cell and Gene Therapies to Treat, Prevent, and Potentially Cure Diseases	Phase 1 studies of CD19 CAR-T cell immunotherapy for large B cell lymphoma.	Cameron Turtle, MBBS, PhD, FRACP, FRCPA Professor and CLEARbridge Chair in Cancer Immunotherapy, University of Sydney
15-Oct	On Demand	Emerging Therapeutic Modalities: Current Practices, Challenges, Novel Solutions	When good cells go bad: Causes and consequences of aneuploidy in human pluripotent stem cells	Ivana Barbaric, DPhil Professor of Stem Cell Biology, The University of Sheffield